The AD-protective apoE2 isoform, which has reduced binding to LDLR and increased association with lipids compared to apoE3, can potentially improve the transport of Aβ out of the brain, likely via the CSF [49] (Figure 7A). Here, LDLR is linked to Alzheimer disease.